Literature DB >> 19883653

Beta-adrenergic receptor signaling in the heart: role of CaMKII.

Michael Grimm1, Joan Heller Brown.   

Abstract

The multifunctional Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) targets a number of Ca(2+) homeostatic proteins and regulates gene transcription. Many of the substrates phosphorylated by CaMKII are also substrates for protein kinase A (PKA), the best known downstream effector of beta-adrenergic receptor (beta-AR) signaling. While PKA and CaMKII are conventionally considered to transduce signals through separate pathways, there is a body of evidence suggesting that CaMKII is activated in response to beta-AR stimulation and that some of the downstream effects of beta-AR stimulation are actually mediated by CaMKII. The signaling pathway through which beta-AR stimulation activates CaMKII, in parallel with or downstream of PKA, is not well-defined. This review considers the evidence for and mechanisms by which CaMKII is activated in response to beta-AR stimulation. In addition the potential role of CaMKII in beta-AR regulation of cardiac function is considered. Notably, although many CaMKII targets (e.g., phospholamban or the ryanodine receptor) are central to the regulation of Ca(2+) handling, and effects of CaMKII on Ca(2+) handling are detectable, inhibition or gene deletion of CaMKII has relatively little effect on the acute physiological contractile response to beta-AR. On the other hand CaMKII expression and activity are increased in heart failure, a pathophysiological condition characterized by chronic stimulation of cardiac beta-ARs. Blockade of beta-ARs is an accepted therapy for treatment of chronic heart failure although the rationale for its beneficial effects in cardiomyocytes is uncertain. There is growing evidence that inhibition or gene deletion of CaMKII also has a significant beneficial impact on the development of heart failure. The possibility that excessive beta-AR stimulation is detrimental because of its effects on CaMKII mediated Ca(2+) handling disturbances (e.g., ryanodine receptor phosphorylation and diastolic SR Ca(2+) leak) is an intriguing hypothesis that merits future consideration. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19883653      PMCID: PMC2896283          DOI: 10.1016/j.yjmcc.2009.10.016

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  127 in total

1.  PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts.

Authors:  S O Marx; S Reiken; Y Hisamatsu; T Jayaraman; D Burkhoff; N Rosemblit; A R Marks
Journal:  Cell       Date:  2000-05-12       Impact factor: 41.582

2.  In vivo ventricular gene delivery of a beta-adrenergic receptor kinase inhibitor to the failing heart reverses cardiac dysfunction.

Authors:  A S Shah; D C White; S Emani; A P Kypson; R E Lilly; K Wilson; D D Glower; R J Lefkowitz; W J Koch
Journal:  Circulation       Date:  2001-03-06       Impact factor: 29.690

3.  Ryanodine receptor/calcium release channel PKA phosphorylation: a critical mediator of heart failure progression.

Authors:  Xander H T Wehrens; Stephan E Lehnart; Steven Reiken; John A Vest; Anetta Wronska; Andrew R Marks
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-06       Impact factor: 11.205

4.  Phospholamban phosphorylation in intact ventricles. Phosphorylation of serine 16 and threonine 17 in response to beta-adrenergic stimulation.

Authors:  A D Wegener; H K Simmerman; J P Lindemann; L R Jones
Journal:  J Biol Chem       Date:  1989-07-05       Impact factor: 5.157

5.  Epac and phospholipase Cepsilon regulate Ca2+ release in the heart by activation of protein kinase Cepsilon and calcium-calmodulin kinase II.

Authors:  Emily A Oestreich; Sundeep Malik; Sanjeewa A Goonasekera; Burns C Blaxall; Grant G Kelley; Robert T Dirksen; Alan V Smrcka
Journal:  J Biol Chem       Date:  2008-10-27       Impact factor: 5.157

6.  Adrenergic regulation of cardiac contractility does not involve phosphorylation of the cardiac ryanodine receptor at serine 2808.

Authors:  Scott M MacDonnell; Gerardo García-Rivas; Joseph A Scherman; Hajime Kubo; Xiongwen Chen; Héctor Valdivia; Steven R Houser
Journal:  Circ Res       Date:  2008-04-03       Impact factor: 17.367

7.  Unchanged beta-adrenergic stimulation of cardiac L-type calcium channels in Ca v 1.2 phosphorylation site S1928A mutant mice.

Authors:  Toni Lemke; Andrea Welling; Carl Johannes Christel; Anne Blaich; Dominik Bernhard; Peter Lenhardt; Franz Hofmann; Sven Moosmang
Journal:  J Biol Chem       Date:  2008-09-30       Impact factor: 5.157

8.  Calmodulin kinase II is required for fight or flight sinoatrial node physiology.

Authors:  Yuejin Wu; Zhan Gao; Biyi Chen; Olha M Koval; Madhu V Singh; Xiaoqun Guan; Thomas J Hund; William Kutschke; Satyam Sarma; Isabella M Grumbach; Xander H T Wehrens; Peter J Mohler; Long-Sheng Song; Mark E Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-10       Impact factor: 11.205

9.  Calmodulin mediates differential sensitivity of CaMKII and calcineurin to local Ca2+ in cardiac myocytes.

Authors:  Jeffrey J Saucerman; Donald M Bers
Journal:  Biophys J       Date:  2008-08-08       Impact factor: 4.033

10.  Multifunctional Ca2+/calmodulin-dependent protein kinase mediates Ca(2+)-induced enhancement of the L-type Ca2+ current in rabbit ventricular myocytes.

Authors:  M E Anderson; A P Braun; H Schulman; B A Premack
Journal:  Circ Res       Date:  1994-11       Impact factor: 17.367

View more
  103 in total

Review 1.  Cardiac hypertrophy and heart failure development through Gq and CaM kinase II signaling.

Authors:  Shikha Mishra; Haiyun Ling; Michael Grimm; Tong Zhang; Don M Bers; Joan Heller Brown
Journal:  J Cardiovasc Pharmacol       Date:  2010-12       Impact factor: 3.105

Review 2.  CaMKII in myocardial hypertrophy and heart failure.

Authors:  Mark E Anderson; Joan Heller Brown; Donald M Bers
Journal:  J Mol Cell Cardiol       Date:  2011-01-27       Impact factor: 5.000

Review 3.  Is CaMKII a link between inflammation and hypertrophy in heart?

Authors:  Madhu V Singh; Mark E Anderson
Journal:  J Mol Med (Berl)       Date:  2011-01-29       Impact factor: 4.599

4.  Cardiac myosin binding protein C and its phosphorylation regulate multiple steps in the cross-bridge cycle of muscle contraction.

Authors:  Arthur T Coulton; Julian E Stelzer
Journal:  Biochemistry       Date:  2012-04-06       Impact factor: 3.162

Review 5.  Inherited calcium channelopathies in the pathophysiology of arrhythmias.

Authors:  Luigi Venetucci; Marco Denegri; Carlo Napolitano; Silvia G Priori
Journal:  Nat Rev Cardiol       Date:  2012-06-26       Impact factor: 32.419

6.  Time-dependent evolution of functional vs. remodeling signaling in induced pluripotent stem cell-derived cardiomyocytes and induced maturation with biomechanical stimulation.

Authors:  Gwanghyun Jung; Giovanni Fajardo; Alexandre J S Ribeiro; Kristina Bezold Kooiker; Michael Coronado; Mingming Zhao; Dong-Qing Hu; Sushma Reddy; Kazuki Kodo; Krishna Sriram; Paul A Insel; Joseph C Wu; Beth L Pruitt; Daniel Bernstein
Journal:  FASEB J       Date:  2015-12-16       Impact factor: 5.191

Review 7.  Molecular Basis of Atrial Fibrillation Pathophysiology and Therapy: A Translational Perspective.

Authors:  Stanley Nattel; Jordi Heijman; Liping Zhou; Dobromir Dobrev
Journal:  Circ Res       Date:  2020-06-18       Impact factor: 17.367

8.  Gene therapy for inherited arrhythmias.

Authors:  Vassilios J Bezzerides; Maksymilian Prondzynski; Lucie Carrier; William T Pu
Journal:  Cardiovasc Res       Date:  2020-07-15       Impact factor: 10.787

Review 9.  Running forward: new frontiers in endurance exercise biology.

Authors:  Glenn C Rowe; Adeel Safdar; Zolt Arany
Journal:  Circulation       Date:  2014-02-18       Impact factor: 29.690

10.  Imatinib activates pathological hypertrophy by altering myocyte calcium regulation.

Authors:  Larry A Barr; Catherine A Makarewich; Remus M Berretta; Hui Gao; Constantine D Troupes; Felix Woitek; Fabio Recchia; Hajime Kubo; Thomas Force; Steven R Houser
Journal:  Clin Transl Sci       Date:  2014-06-16       Impact factor: 4.689

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.